Welcome to Kazia

MENU

Welcome to Kazia Therapeutics

Novel Australian drug GDC-0084 for glioblastoma brain cancer starts Phase II clinical trial in US read more

Watch Q&A with Kazia CEO as we launch GDC-0084 Phase II trial view video

Learn why GDC-0084 is a novel potential treatment for glioblastoma brain cancer read more

Kazia Therapeutics partners with the world’s leading researchers and drug developers to bring forward a diversified portfolio of new cancer therapies.

Our programs are scientifically innovative and commercially valuable. Above all, we work for the benefit of patients with the greatest unmet need.

News

..

More News
Media

11-Jul-2018

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase.

More Media

Insights

25-Jul-2018New

Sydney Shareholder Information Session July 2018

11-Jul-2018

What makes our cancer therapies different

More Insights
Resources

14-MAY-2018

Edison Research - GDC-0084 Phase II underway

3-APR-2018

NDF Research Re-initiates Research Coverage on Kazia Therapeutics

14-DEC-2017

Cedrus Investments - Kazia Therapeutics Targeting Unmet Oncological Needs
Share Price

Historical Prices

SITE BY SPATIAL DESIGN